Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference
04 Oktober 2023 - 6:00PM
Business Wire
Preclinical study shows Adicet’s Allogeneic
Gamma Delta T Cell Platform may be a Promising Approach for
Prostate Cancer
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced a poster presentation at the
upcoming 2023 International Conference on Molecular Targets and
Cancer Therapeutics hosted by the American Association for Cancer
Research, the National Cancer Institute, and the European
Organisation for Research and Treatment of Cancer to be held in
Boston from October 11-15, 2023.
Details of the poster presentation is as follows:
Abstract Title: Characterization of Allogeneic CAR γδ1 T
Cell Therapy for Prostate Cancer Targeting a Novel Dimeric Epitope
on PSMA (Prostate-Specific Membrane Antigen)
Poster Number: C117
Presenting Author: Nitya Ramadoss, PhD
Date/Time: Saturday, October 14, from 12:30 p.m. - 4:00
p.m. PDT
Session Location: Level 2, Exhibit Hall D
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and chimeric antigen adaptors (CAds), to enhance selective tumor
targeting and facilitate innate and adaptive anti-tumor immune
response for durable activity in patients. For more information,
please visit our website at https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231004175869/en/
Adicet Bio., Inc. Investor and Media Contacts Anne
Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
Von Mai 2023 bis Mai 2024